HISCOX LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,142 GBX | -.--% |
|
-2.06% | +8.35% |
| May. 08 | UBS raises Centrica to 'buy' from 'neutral | AN |
| May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 4,108 | 3,443 | 2,982 | 3,776 | 3,659 | 3,912 | - | - |
| Enterprise Value (EV) 1 | 3,234 | 3,443 | 2,982 | 3,776 | 3,659 | 4,425 | 4,425 | 4,425 |
| P/E ratio | 108 x | -15.1 x | 21 x | 108 x | 6.64 x | 8.37 x | 7.69 x | 7 x |
| Yield | 2.38% | - | 3.07% | 2.79% | - | 2.82% | 3.13% | 3.31% |
| Capitalization / Revenue | 1.3 x | 1.19 x | 0.93 x | 1.01 x | 1.01 x | 1.01 x | 0.92 x | 0.86 x |
| EV / Revenue | 1.02 x | 1.19 x | 0.93 x | 1.01 x | 1.01 x | 1.14 x | 1.04 x | 0.98 x |
| EV / EBITDA | - | - | - | 29,446,460 x | - | - | - | - |
| EV / FCF | -71,454,479 x | -25,379,213 x | 347,702,891 x | 12,689,127 x | - | - | - | - |
| FCF Yield | -0% | -0% | 0% | 0% | - | - | - | - |
| Price to Book | 2.32 x | 2.01 x | 1.52 x | 1.84 x | - | 1.37 x | 1.22 x | 1.07 x |
| Nbr of stocks (in thousands) | 288,502 | 346,382 | 346,463 | 346,543 | 347,168 | 342,520 | - | - |
| Reference price 2 | 14.24 | 9.940 | 8.608 | 10.90 | 10.54 | 11.42 | 11.42 | 11.42 |
| Announcement Date | 3/2/20 | 3/3/21 | 3/2/22 | 3/8/23 | 3/5/24 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3,157 | 2,891 | 3,201 | 3,735 | 3,621 | 3,890 | 4,269 | 4,529 |
| EBITDA | - | - | - | 128.2 | - | - | - | - |
| EBIT 1 | 70.18 | -160.7 | 180.6 | 77.57 | - | 569.3 | 631 | 655.3 |
| Operating Margin | 2.22% | -5.56% | 5.64% | 2.08% | - | 14.64% | 14.78% | 14.47% |
| Earnings before Tax (EBT) 1 | 41.59 | -192.4 | 143.1 | 37.73 | 492.9 | 523.2 | 583.2 | 626 |
| Net income 1 | 38.3 | -210.5 | 142.1 | 35.2 | 560.7 | 465.7 | 500.4 | 533.4 |
| Net margin | 1.21% | -7.28% | 4.44% | 0.94% | 15.48% | 11.97% | 11.72% | 11.78% |
| EPS 2 | 0.1324 | -0.6565 | 0.4102 | 0.1013 | 1.587 | 1.364 | 1.485 | 1.632 |
| Free Cash Flow | -45.26 | -135.7 | 8.577 | 297.5 | - | - | - | - |
| FCF margin | -1.43% | -4.69% | 0.27% | 7.97% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | 232.06% | - | - | - | - |
| FCF Conversion (Net income) | - | - | 6.04% | 845.32% | - | - | - | - |
| Dividend per Share 2 | 0.3395 | - | 0.2642 | 0.3039 | - | 0.3221 | 0.3572 | 0.3778 |
| Announcement Date | 3/2/20 | 3/3/21 | 3/2/22 | 3/8/23 | 3/5/24 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,326 | 1,701 | 1,285 | 1,746 | 1,382 | 2,169 | 1,498 | 2,141 | 1,477 | 2,324 | 1,592 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | - | - | - | - | - | - | 293.4 | 293.4 |
| Operating Margin | - | - | - | - | - | - | - | - | - | 12.62% | 18.43% |
| Earnings before Tax (EBT) 1 | - | -105.7 | -92.65 | 95.98 | 43 | -87.91 | 128.4 | 208.1 | 284.4 | 220.7 | 286 |
| Net income 1 | - | -114.5 | - | 85.62 | 52.81 | -71.29 | 108.7 | 196.6 | 363.8 | 196 | 254.2 |
| Net margin | - | -6.73% | - | 4.9% | 3.82% | -3.29% | 7.26% | 9.18% | 24.64% | 8.43% | 15.97% |
| EPS 2 | - | -0.3821 | - | 0.2475 | 0.1521 | -0.2071 | 0.3148 | 0.5564 | 1.029 | 0.5641 | 0.7458 |
| Dividend per Share 2 | - | - | - | 0.0828 | - | 0.0990 | 0.2026 | 0.0983 | - | 0.0829 | 0.1673 |
| Announcement Date | 3/2/20 | 8/3/20 | 3/3/21 | 8/3/21 | 3/2/22 | 8/3/22 | 3/8/23 | 8/9/23 | 3/5/24 | - | - |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 513 | 513 | 513 |
| Net Cash position 1 | 874 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -45.3 | -136 | 8.58 | 298 | - | - | - | - |
| ROE (net income / shareholders' equity) | 2.2% | -11.8% | 8.1% | 1.7% | - | 17.2% | 17.1% | 16% |
| ROA (Net income/ Total Assets) | 0.42% | -2.22% | 1.37% | 0.3% | - | 5.05% | 5.17% | 4.84% |
| Assets 1 | 9,119 | 9,463 | 10,388 | 11,636 | - | 9,223 | 9,684 | 11,014 |
| Book Value Per Share 2 | 6.140 | 4.960 | 5.670 | 5.920 | - | 8.360 | 9.370 | 10.60 |
| Cash Flow per Share 2 | 0.1100 | -0.2600 | 0.0400 | 0.9000 | - | 1.130 | 1.570 | 1.830 |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 3/3/21 | 3/2/22 | 3/8/23 | 3/5/24 | - | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
11.42
GBP
Average target price
12.93
GBP
Spread / Average Target
+13.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.35% | 4.98B | |
| +53.84% | 67.71B | |
| +16.34% | 52.31B | |
| +13.23% | 49.39B | |
| +19.67% | 44.21B | |
| +38.21% | 38.39B | |
| +77.48% | 33.19B | |
| +11.86% | 29.8B | |
| +25.50% | 25.35B | |
| -0.43% | 21.46B |
- Stock Market
- Equities
- HSX Stock
- Financials Hiscox Ltd
